학술논문
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)
Document Type
Article
Author
Kaklamani, Virginia G.; Bidard, Francois Clement; Neven, Patrick; Montero, Alberto J.; Mouret-Reynier, Marie-Ange; Sohn, Joohyuk; Taylor, Donatienne; Forget, Frederic; Harnden, Kathleen Kiernan; Khong, Hung T.; Kocsis, Judit; Dalenc, Florence; Dillon, Patrick Michael; Waters, Simon; García-Sáenz, José A.; Aftimos, Philippe Georges; Cortes, Javier; Scartoni, Simona; Habboubi, Nassir; Bardia, Aditya
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p1070-1070, 1p
Subject
Language
ISSN
0732183X